"Oximes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that contain the radical R2C=N.OH derived from condensation of ALDEHYDES or KETONES with HYDROXYLAMINE. Members of this group are CHOLINESTERASE REACTIVATORS.
| Descriptor ID |
D010091
|
| MeSH Number(s) |
D02.092.570.665
|
| Concept/Terms |
Oximes- Oximes
- Hydroxyimino Compounds
- Compounds, Hydroxyimino
|
Below are MeSH descriptors whose meaning is more general than "Oximes".
Below are MeSH descriptors whose meaning is more specific than "Oximes".
This graph shows the total number of publications written about "Oximes" by people in this website by year, and whether "Oximes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oximes" by people in Profiles.
-
Synthesis, Characterization and Antimicrobial Activity of Trimethylantimony(V) Biscyanoximates, a New Family of Antimicrobials. Molecules. 2024 Dec 06; 29(23).
-
Dynamic neuroreceptor positron emission tomography in non-anesthetized rats using point source based motion correction: A feasibility study with [11C]ABP688. J Cereb Blood Flow Metab. 2024 Oct; 44(10):1852-1866.
-
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gynecol Oncol. 2024 07; 186:61-68.
-
Interactions of arylhydroxylamines and alkylaldoximes with a rhodium porphyrin. J Inorg Biochem. 2023 10; 247:112337.
-
Non-Antibiotic Antimony-Based Antimicrobials. Molecules. 2022 Oct 23; 27(21).
-
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
-
The apoptotic effect of GSK-3 inhibitors: BIO and CHIR 98014 on H1975 lung cancer cells through ROS generation and mitochondrial dysfunction. Biotechnol Lett. 2020 Aug; 42(8):1351-1368.
-
Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient. Childs Nerv Syst. 2020 01; 36(1):203-207.
-
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst. 2016 Feb; 108(2).